CO4410317A1 - Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos. - Google Patents

Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.

Info

Publication number
CO4410317A1
CO4410317A1 CO95043013A CO95043013A CO4410317A1 CO 4410317 A1 CO4410317 A1 CO 4410317A1 CO 95043013 A CO95043013 A CO 95043013A CO 95043013 A CO95043013 A CO 95043013A CO 4410317 A1 CO4410317 A1 CO 4410317A1
Authority
CO
Colombia
Prior art keywords
alcoholism
selective
inhibitor
opioid antagonist
receptation
Prior art date
Application number
CO95043013A
Other languages
English (en)
Inventor
Leonard Cook
Original Assignee
Du Pont Merck Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma Co filed Critical Du Pont Merck Pharma Co
Publication of CO4410317A1 publication Critical patent/CO4410317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. METODO DE TRATAMIENTO PARA EL ALCOHOLISMO Y DEPENDENCIA ALCOHOLICA QUE COMPRENDE LA ADMINIS- TRACION A UN MAMIFERO DE UNA CANTIDAD TERAPEUTICA- MENTE EFECTIVA DE UNA COMBINACION SINERGISTICA DE: (i) AL MENOS UN ANTAGONISTA OPIOIDE; Y (ii) AL MENOS UN INHIBIDOR DE RECAPTACION SELECTIVA DE SE- ROTONINA. 14. UNA COMPOSICION FARMACEUTICA QUE COMPRENDE U- NA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UNA COM- BINACION SINERGISTICA DE: AL MENOS UN ANTAGONISTA OPIOIDE; Y (ii) AL MENOS UN INHIBIDOR DE RECAPTA- CION SELECTIVA DE SEROTONINA. 15. UNA COMPOSICION FARMACEUTICA DE LA REIVINDI- CACION 14 EN DONDE EL ANTAGONISTA OPIOIDE ANTES MENCIONADO ES SELECCIONADO DEL GRUPO QUE CONSTA DE NALTREXONA, NALMEFENO Y NALOXONA. 17. UNA COMPOSICION FARMACEUTICA DE LA REIVINDI- CACION 14 EN DONDE EL INHIBIDOR DE RECAPTACION SE- LECTIVA DE SEROTONINA ES SELECCIONADO DEL GRUPO QUE CONSTA DE FLUOXETINA, SERTRALINA, PAROXETINA, FLUROXAMINA, VENLAFAXINA Y NEFAZOLONA.
CO95043013A 1994-09-19 1995-09-19 Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos. CO4410317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30885994A 1994-09-19 1994-09-19

Publications (1)

Publication Number Publication Date
CO4410317A1 true CO4410317A1 (es) 1997-01-09

Family

ID=23195683

Family Applications (1)

Application Number Title Priority Date Filing Date
CO95043013A CO4410317A1 (es) 1994-09-19 1995-09-19 Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.

Country Status (11)

Country Link
US (1) US5958962A (es)
EP (1) EP0782445B1 (es)
AT (1) ATE214276T1 (es)
AU (1) AU3419995A (es)
CA (1) CA2197554A1 (es)
CO (1) CO4410317A1 (es)
DE (1) DE69525847T2 (es)
DK (1) DK0782445T3 (es)
HR (1) HRP950485A2 (es)
WO (1) WO1996009047A1 (es)
ZA (1) ZA957891B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
KR100412327B1 (ko) 1997-07-01 2003-12-31 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
CN1261792A (zh) * 1997-07-01 2000-08-02 辉瑞产品公司 明胶封装的舍曲林溶液剂型
AU1018801A (en) * 1999-10-29 2001-05-14 Novo Nordisk A/S Use of 3,4-substituted piperidines
PT2277521E (pt) 2000-02-08 2015-07-01 Euro Celtique Sa Formulações orais de agonistas de opióides resistentes a adulteração
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP4545584B2 (ja) 2002-05-17 2010-09-15 デューク ユニバーシティ 肥満を治療するための方法
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
US20040253642A1 (en) * 2003-06-06 2004-12-16 Grant Zimmermann System and method for multidimensional evaluation of combinations of compositions
WO2005070461A2 (en) 2004-01-13 2005-08-04 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
AU2006323048B2 (en) 2005-11-22 2013-07-04 Nalpropion Pharmaceuticals Llc Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
CA2668884C (en) 2006-11-09 2016-11-01 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
CA2102507A1 (en) * 1991-05-07 1992-11-08 Judith P. Kitchell A controlled, sustained release delivery system for smoking cessation
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Also Published As

Publication number Publication date
DK0782445T3 (da) 2002-05-06
ATE214276T1 (de) 2002-03-15
WO1996009047A1 (en) 1996-03-28
DE69525847T2 (de) 2002-09-05
AU3419995A (en) 1996-04-09
HRP950485A2 (en) 1997-08-31
ZA957891B (en) 1997-03-19
US5958962A (en) 1999-09-28
EP0782445A1 (en) 1997-07-09
CA2197554A1 (en) 1996-03-28
EP0782445B1 (en) 2002-03-13
DE69525847D1 (de) 2002-04-18

Similar Documents

Publication Publication Date Title
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
AR023129A1 (es) Composiciones para mejorar la fertilidad
SI1691892T1 (sl) Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
AR033342A1 (es) Una composicion otica topica o intranasal para tratar el dolor otico y el uso topico de agonistas de opioides kapa para tratar el dolor otico
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
MX9401191A (es) Compuestos del grupo sulfamoilo y amidino, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DE60038290D1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
WO2004093819A3 (en) Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
BRPI0409128A (pt) uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE60236496D1 (de) Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
TR199700878T1 (xx) Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar.
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
RU94031161A (ru) Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba